Circulating soluble endoglin modifies the inflammatory response in mice by Ruiz-Remolina, Laura et al.
RESEARCH ARTICLE
Circulating soluble endoglin modifies the
inflammatory response in mice
Laura Ruiz-Remolina1,2, Claudia Ollauri-Ibáñez1,2, Lucı́a Pérez-Roque1,2, Elena Núñez-
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Abstract
Inflammation is associated with every health condition, and is an important component of
many pathologies such as cardiovascular diseases. Circulating levels of soluble endoglin
have been shown to be higher in the serum of patients with cardiovascular diseases with a
significant inflammatory component. The aim of this study was to evaluate the implication of
circulating soluble endoglin in the inflammatory response. For this purpose, a transgenic
mouse expressing human soluble endoglin (sEng+) was employed, and three different
inflammatory approaches were used to mimic inflammatory conditions in different tissues.
This study shows that control sEng+ mice have a normal inflammatory state. The lung and
kidney injury induced by the inflammatory agents was reduced in sEng+ mice, especially
the intra-alveolar and kidney infiltrates, suggesting a possible reduction in inflammation
induced by soluble endoglin. To deepen into this possible effect, the leukocyte number in
the bronchoalveolar lavage and air pouch lavage was evaluated and a significant reduction
of neutrophil infiltration in LPS-treated lungs and ischemic kidneys from sEng+ with respect
to WT mice was observed. Additionally, the mechanisms through which soluble endoglin
prevents inflammation were studied. We found that in sEng+ animals the increment of
proinflammatory cytokines, TNFα, IL1β and IL6, induced by the inflammatory stimulus
was reduced. Soluble endoglin also prevents the augmented adhesion molecules, ICAM,
VCAM and E-selectin induced by the inflammatory stimulus. In addition, vascular permeabil-
ity increased by inflammatory agents was also reduced by soluble endoglin. These results
suggest that soluble endoglin modulates inflammatory-related diseases and open new per-
spectives leading to the development of novel and targeted approaches for the prevention
and treatment of cardiovascular diseases.
Introduction
Inflammation is the body’s response to tissue injury, infection or invasion by microorganisms
and its purpose is to keep maintain homeostasis [1]. Inflammation has been found to be associ-
ated with every health condition, and is an important secondary component of many patholo-
gies. Inflammation, often named the secret killer, is a key factor in a large group of diseases
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López-Novoa JM, et al. (2017) Circulating soluble
endoglin modifies the inflammatory response in
mice. PLoS ONE 12(11): e0188204. https://doi.org/
10.1371/journal.pone.0188204
Editor: Bernhard Ryffel, Centre National de la
Recherche Scientifique, FRANCE
Received: August 10, 2017
Accepted: November 2, 2017
Published: November 16, 2017
Copyright: © 2017 Ruiz-Remolina et al. This is an
open access article distributed under the terms of
the Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The studies carried out by the authors
have been supported by grants from the Ministerio
de Economı́a y Competitividad of Spain (SAF2013-
45784-R to ARB), the Junta de Castilla y León
(Grant No GR-100 to JMLN), Sociedad Española de
Nefrologı́a (SENEFRO to ARB), Fundación Renal
Iñigo Alvarez de Toledo to JMLN, and Kidney
Research Network (REDINREN, grants RD06/
affecting and killing millions of people every year. Examples of inflammatory diseases or dis-
eases with key inflammatory components include arthritis, cardiovascular diseases, hyperten-
sion, obesity, insulin resistance, arthritis, alzheimer’s and parkinson’s diseases, peritonitis,
colitis and several types of cancer [2,3]. An impaired immune response is a driver in the patho-
genesis of many diseases, and its untimely resolution represents a process, which if targeted,
could provide new therapeutic avenues for a multitude of diseases treatments. Currently, anti-
inflammatory drugs, both NSAIDs and steroidal, fail to deliver a solution because they tackle
only parts of the inflammatory cascade and induce unacceptable side effects. Drug hypersensi-
tivity reactions are increasing in the 21st Century with the ever-expanding availability of new
therapeutic agents. During inflammation there is an increased production of various media-
tors, including proinflammatory cytokines and eicosanoids [4], which have been used as both
inflammation biomarkers and therapeutic targets. Soluble endoglin (sEng) is emerging as a
new biomarker for several cardiovascular diseases. Circulating levels of soluble endoglin have
been shown to be higher in the serum of patients with preeclampsia, hypercholesterolemia,
atherosclerosis, diabetes mellitus and hypertension [5–8], diseases which all have a significant
inflammatory component [2,3].
Soluble endoglin is a glycoprotein generated by the cleavage of the extracellular domain of
the membrane-bound endoglin [5] by a MT1-MMP (membrane-type metalloprotease-1) as
the main endoglin-shedding protease [9]. Increased levels of soluble endoglin in plasma have
been correlated with predicting complications in myocardial infarction [10], acute heart failure
[11,12], cardiovascular events in patients with chronic coronary artery disease [13], cardiovas-
cular alterations in patients with hypertension and diabetes, [8] and has diagnostic and prog-
nostic value in preeclampsia [5]. Soluble endoglin appears to be a good biomarker of damage
in diseases in which it has been related. However, how endoglin is involved in the pathogenesis
has not been researched in-depth. There are some studies postulating that the effect of soluble
endoglin is produced by antagonizing the effect of membrane endoglin or by sequestering the
ligand. Soluble endoglin can bind several ligands, among them TGF-β1, BMP-9 and BMP-10
[5,14]. When soluble endoglin binds circulating TGF-β1, the availability of this cytokine to
interact with its membrane receptors decreases, as soluble endoglin is unable to interact
directly with the extracellular region of TGF-β receptors type I and type II [15].
To gain a wide-ranging understanding of the therapeutic areas of inflammatory diseases,
we have study the effect of soluble endoglin on inflammation. The implication of soluble
endoglin on the inflammation related-diseases could open a new therapeutic area for the
treatment of these diseases. The aim of this study was to evaluate the implication of soluble
endoglin in the inflammatory response of an in vivo animal model. To this end, a transgenic
mouse model expressing human soluble endoglin (sEng+) was employed, and three differ-
ent inflammatory approaches, lipopolysaccharide in lung, carrageenan in air pouch and
renal ischemia-reperfusion, were used to mimic the inflammatory conditions. This model
permits the direct relation between circulating soluble endoglin and the inflammatory pro-
cesses to be analyzed.
Materials and methods
Ethics statement
All animal procedures were conducted in strict compliance with the European Community
Council Directive (63/2010/UE) and Spanish legislation and the protocols were approved by
the University of Salamanca Ethics Committee. The animals were housed under SPF condi-
tions at the SEA Animal House of the NUCLEUS platform at the University of Salamanca
(ES372740000046).
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Reagents
λ-Carrageenan (catalog #2329535), lipopolysaccharide (LPS) (catalog #L3129) and Fluorescein
Isotiocyanate Dextran (FITC-Dextran) (catalog #FD40) were purchased from Sigma-Aldrich
(St Louis, MO, USA). Recombinant human endoglin (rhEndoglin; Eng) (Catalog #1097-EN-
025) was purchased from R&D Systems (Minneapolis, MN, USA). Isoflurane and buprenor-
phine (Schering-Plough; Madrid, Spain) were used for anesthesia and analgesia respectively.
Mice
A mouse line expressing human soluble endoglin (sEng+) was generated at the Genetically
Modified Organism Unit (NUCLEUS Platform, University of Salamanca, Spain) as it has been
already reported [16]. The cDNA corresponding to the extracellular domain of endoglin was
cloned under the control of the CMV-actin gene promoter. Linear DNA fragments for micro-
injection were obtained by SalI/KpnI digestion and injected into CBA x C57BL/6J fertilized
eggs as previously described [16]. The progeny was screened for the endoglin transgene by
polymerase chain reaction analysis of tail DNA. The studies reported here were performed on
the F7 generation of 6-8-month-old male mice, weighing 25–30 g. The animals were given
standard laboratory chow (Panlab; Barcelona, Spain) and water ad libitum, and housed in the
animal experimental service at NUCLEUS Platform, with a temperature of 22–24˚C, humidity
of 60–65%, and 12 h light/dark cycles, along with their wild-type littermates. Animals showed
no signs of severe illness following any of the laboratory procedures. After surgery, a single
dose of the analgesic buprenorphine was injected subcutaneously to reduce pain in the post-
surgery phase. Animals were kept warm during 3 h, and the condition of the animals was mon-
itored every 3 h after the laboratory procedure. No animals died due to the experimental pro-
cedures. Mice were always euthanized in a CO2 chamber.
Study design
Lipopolysaccharide-induced acute lung injury. The study was carried out using a mouse
model of acute lung injury (ALI) induced by aerosolized administration of LPS (Fig 1A). Mice
were randomly divided into two groups: the sham group (control), which were exposed to
nebulized NaCl solution, and the LPS group (LPS), which were exposed to nebulized LPS. The
mice were placed into a chamber and exposed to aerosolized LPS (5 mg/ml in sterile 0,9%
NaCl solution) for 30 min using a nebulizer unit driven by a pressure of 2 bars. The control,
vehicle treated mice, were aerosolized with a 0,9% NaCl solution. 48 h after LPS exposure, the
animals were euthanized and blood was collected through cardiac puncture and later centri-
fuged at 7 000 g for 4 min at 4˚C for obtaining a plasma sample. Then, bronchoalveolar lavage
(BAL) was carried out by instilling sterile endotoxin-free phosphate buffered saline (PBS) into
the lungs via tracheotomy, which was then centrifuged at 300 g for 10 min at 4˚C. The super-
natant was subsequently collected and analyzed for the presence of proinflammatory cyto-
kines, and protein levels were determined. The cell pellet was resuspended in PBS and used for
leukocyte quantification using a Neubauer hemocytometer. The protocol is available in http://
dx.doi.org/10.17504/protocols.io.j8ecrte.
The lungs of each animal were removed and divided into two parts: the left lower lobe was
snap-frozen and later processed for obtaining lung homogenates, and the rest of the material
was fixed in 4% formalin for histological evaluation.
Carrageenan-induced air-pouch inflammation. Air pouches were created on the backs
of WT and sEng+ mice by subcutaneous injection of 3 ml of filtered air. The pouches were re-
inflated on day 4 with an additional 2 ml of filtered air, and after 7 days a synovial-like epithe-
lium was present in the air pouch [17]. Inflammation was induced by injecting 500 μl of 1%
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carrageenan in PBS into the air pouch of the anesthetized mice. The pouches of the control
mice were injected with only 500 μl of PBS solution. After 24 h, the mice were euthanized, air
pouch lavages were performed with 2 ml of PBS (Fig 1B) and the liquid was centrifuged at 300
g for 10 min at 4˚C. Air pouch lavages were analyzed for the presence of proinflammatory
cytokines, and protein levels were determined. Leukocyte identification was performed using
an automated hematology analyzer (ADVIA1 120; Siemens Healthcare, Erlanger, Germany).
The protocol is available in http://dx.doi.org/10.17504/protocols.io.j8dcrs6.
Fig 1. Methods timeline. (A) Aerosolized LPS (5mg/ml) was administered by inhalation to WT and sEng
+ mice (Day 1). 48 h after LPS exposure, mice were euthanized and BAL was carried out by instilling sterile
PBS into the lungs via tracheotomy (Day 3). BAL was used for the analysis of proinflammatory cytokines,
leukocytes and protein determination. (B) An air pouch was created on the back of WT and sEng+ mice by
subcutaneous injection of 3 ml filtered air (Day 1). The pouch was re-inflated with an additional 2 ml of filtered
air (Day 4). Inflammation was induced by injecting 500 μl of 1% carrageenan in PBS into the air pouch of the
anesthetized mice (Day 7). Mice were sacrificed and air pouch lavages were performed with 2 ml of PBS (Day
8). Air pouch lavage was used for analysis of proinflammatory cytokines, leukocytes and protein determination.
(C) Aerosolized LPS (5mg/ml) was administered by inhalation to WT and sEng+ mice (Day 1). 24 h after LPS
exposure, 40 kDa FITC-Dextran (25 mg/ml) was injected into the retroorbital venous sinus to WT and sEng
+ mice. 30 min later, the mice were euthanized (Day 2), and BAL was collected by instilling PBS into the lungs
via tracheotomy. (D) Male mice were anaesthetized by isoflurane inhalation. Following abdominal incision, left
renal pedicle was bluntly dissected and a microvascular clamp was placed on the left renal pedicle for 30 min.
After a 30-min ischemia, the clamps were removed and the wounds sutured. After closure, animals were
subcutaneously injected with 0,5 ml of PBS (Day 1). 48 h later, the mice were euthanized and blood and the
kidneys were collected (Day 3).
https://doi.org/10.1371/journal.pone.0188204.g001
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Ischemia-reperfusion-induced acute kidney injury. Ischemia-reperfusion injury (IRI) is
the main cause of acute renal failure and is characterized by an inflammatory reaction, tubular
necrosis and fibrosis. In this work, an established model of renal IRI in mice was used [18],
where male mice were anaesthetized by isoflurane inhalation. A microvascular clamp (Roboz
Surgical Instrument, Rockville, MD, USA) was placed on the left renal pedicle, and after 30
min of ischemia, the clamp was removed and the wound sutured. Then, the animals were left
to recover, with free access to food and water. Sham-operated mice underwent the same surgi-
cal procedure without clamping the renal pedicle (Fig 1D). 48 h after ischemia, the mice were
euthanized, blood was collected through cardiac puncture and later centrifuged to obtain a
plasma sample.
The kidneys were removed from each animal and divided into two parts: one was snap-fro-
zen and later processed to obtain kidney homogenates, and the rest was fixed in 4% formalin
for histological evaluation. The protocol is available in http://dx.doi.org/10.17504/protocols.io.
j8gcrtw.
Histological analysis
Lung and kidney tissue was fixed in 4% neutral-buffered formalin and subsequently
embedded in paraffin. Three-mm thick sections were stained with hematoxylin and eosin
(H&E) using a standard protocol [19]. The sections were analyzed by light microscopy and
images were taken with an Olympus DP70 digital camera system in an Olympus BX51F
microscope. Histological changes were evaluated by a pathologist blind to the treatment
regimen. A scoring system to grade the degree of lung and kidney injury was employed
[20,21] based on the histological features specified in Tables 1 and 2. Each feature was
graded as absent, mild, moderate, or severe, with a score of 0–3. A total score was calculated
for each animal.
Protein determination
Protein concentration in BAL and the air pouch lavage was quantified using the DC protein
Assay kit (Bio-Rad; Hercules, CA, USA). Absorbance was measured at 750 nm by an absor-
bance plate reader (BIOTEK Instrument; Winooski, VT, USA) and the results were analyzed
using the Gen 5 program (BIOTEK Instrument; Winooski, VT, USA).
Table 1. Lung injury histopathology score system.
Score 0 1 2 3
Alveolar septae All septae are thin and
delicate
Congested alveolar septae in
less than 1/3 of the field
Congested alveolar septae in 1/
3 to 2/3 of the field
Congested alveolar septae in
greater than 2/3 of the field
Alveolar
hemorrhage
No hemorrhage At least 5 erythrocytes per
alveolus in 1 to 5 alveoli
At least 5 erythrocytes per
alveolus in 5 to 10 alveoli
At least 5 erythrocytes per alveolus
in more than 10 alveoli
Intra-alveolar
fibrin
No intra-alveolar fibrin Fibrin strands in less than 1/3 of
the field
Fibrin strands in 1/3 to 2/3 of the
field




Less than 5 intra-alveolar
cells per field
5 to 10 intra-alveolar cells per
field
10 to 20 intra-alveolar cells per
field
More than 20 intra-alveolar cells
per field
A scoring system to grade the degree of lung injury was employed based on the following histologic features: alveolar septae, alveolar hemorrhage, intra-
alveolar fibrin and intra-alveolar infiltration per field. Each feature was graded as absent, mild, moderate, or severe, with a score of 0–3. A total score was
calculated for each animal.
https://doi.org/10.1371/journal.pone.0188204.t001
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Lung wet-to-dry weight ratio
The lung wet-to-dry weight ratio (W/D) was calculated to assess lung tissue edema. The dia-
phragmatic lobe of the left lung was excised separately and rapidly weighed to obtain the wet-
weight. To determine the stable dry lung weight, the samples were oven dried (60˚C) for 48 h.
Evaluation of lung permeability by FITC-Dextran intravenous injection
FITC-Dextran intravenous injection is a well-established method for measuring lung vascular
permeability. 24 h after LPS exposure, 100 μl of 40 kDa FITC-Dextran was injected into the
retroorbital venous sinus in WT and sEng+ mice, after 30 min the mice were euthanized. BAL
was collected by instilling PBS into the lungs via tracheotomy and the liquid was centrifuged at
300 g for 10 min (Fig 1C). Blood was collected and centrifuged at 7 000 g for 4 min to obtain a
plasma sample. The fluorescence intensity (FI) of the FITC-Dextran in BAL and plasma was
determined at an excitation wavelength of 485 nm and an emission wavelength of 528 nm [22]
using a Synergy H1 plate reader (BIOTEK Instrument; Winooski, VT, USABioTek). The ratio
BAL FI/Plasma FI was calculated to assess lung vascular permeability. The protocol is available
in http://dx.doi.org/10.17504/protocols.io.j8hcrt6.
ELISA kits
Plasma levels of human endoglin were determined by means of Human Endoglin/CD105
Quantikine ELISA kit (R&D System; Minneapolis, MN, USA) according to the manufacturer’s
instructions.
Myeloperoxidase (MPO) activity in snap frozen kidneys was determined using a MPO
Assay Kit (HK210 Hycult1Biotech, Plymouth Meeting, PA, USA) according to the manufac-
turer’s instructions. All the results were normalized using the tissue weight.
Cytokine levels (TNFα, IL1β and IL6) in tissue homogenates, BAL, air pouch lavage and
plasma were measured using the murine cytokine-specific Quantikine ELISA kits (R&D Sys-
tems) according to the manufacturer’s protocol. The tissue homogenates were normalized
using the tissue weight (mg of tissue per sample).
Real-time PCR quantification
For RNA extraction, the tissues were ground and the total RNA was isolated using NucleoS-
pin1 RNA columns (Macherey-Nagel; Düren, Germany) according to the manufacturer’s
instructions. RNA was quantified using NanoDrop1 spectrophotometer ND-1000 (Thermo
Scientific Fisher; Waltham, MA, USA). Total RNA was reverse-transcribed into cDNA with a
High Capacity Reverse-Transcription kit (iScriptTM cDNA synthesis kit; Bio-Rad, Hercules,
Table 2. Kidney injury histopathology score system.
Score 0 1 2 3
Glomerulus No
damage
Thickening of Bowman capsule Retraction of glomerular tuft Glomerular fibrosis
Tubules No
damage
Loss of brush border and/or tubular
debris









Severe confluent neutrophils surrounding
tubules
A scoring system to grade the degree of kidney injury was employed based on the following histologic features: glomerular fibrosis, tubular obstruction and
dilation and neutrophil infiltration per field. Each feature was graded as absent, mild, moderate, or severe, with a score of 0–3. A total score was calculated
for each animal.
https://doi.org/10.1371/journal.pone.0188204.t002
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CA, USA). Real-time PCR detection was performed with a SYBR Green supermix (Bio-Rad,
Hercules, CA, USA). Gene specific primers were designed and checked using the BLAST algo-
rithm [23]. Mouse gene expression was normalized using the expression of GAPDH, β-Actin
and RPS13. The primer pairs used in the analysis are specified in Table 3. The protocol is avail-
able in http://dx.doi.org/10.17504/protocols.io.j8acrse
Western blot assay
Lung and kidney tissues were homogenized in lysis buffer (Tris-ClH pH = 7,5 20mM, NaCl
140mM, EDTA pH = 8 10mM, 10% Glicerol, Igepal CA-630, H2O mQ) containing proteinase
and phosphatase inhibitors (Roche Diagnostics; Mannheim, Germany). Western blot analysis
was performed as we previously described [19]. The primary antibodies used are specified in
Table 4. The protocol is available in http://dx.doi.org/10.17504/protocols.io.j8bcrsn.
Endothelial paracellular permeability assay
The human umbilical vein endothelial cell line EA.hy926 (ATCC; Mannasas, VA, USA) are
hybrid endothelial cells derived by fusing human umbilical vein endothelial cells with the per-
manent human cell line A549. EA.hy926 were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal calf serum (FCS) in an atmosphere of 5% CO2/95% air
and 37˚C.
EA.hy926 cells (105cells/plate) were seeded in transwell inserts (Corning1 BiocoatTM Cell
Culture Inserts Collagen, Type I Rat Tail, 24-Well, 3 μm; Corning, NY, USA) and were cul-
tured to confluence at 24 h. The cells were starved overnight and then activated with LPS
(1 μg/ml) for 4 h. Upper chamber media, containing LPS (1 μg/ml) and soluble endoglin (500
ng/ml) for their respective treatments, were replaced with FITC-Dextran (40 kDa) at 1 mg/ml
in DMEM. The bottom chambers were also replaced with DMEM. After 24 h at 37˚C the
inserts were removed, and the amount of fluorescence in the bottom chambers was measured
using a fluorescence plate reader (Fluoroskan Ascent FL; Thermo Electron Corporation, Wal-
tham, MA, USA). The protocol is available in http://dx.doi.org/10.17504/protocols.io.j8ccrsw.
Table 3. Real-time PCR primer pairs.
Mice primers Forward (5’-3’) Reverse (5’-3’)
GAPDH GTC GGT GTG AAC GGA TTT G GAA TTT GCC GTG AGT GGA GT
β-Actin TCT ACA AAT GTG GCT GAG GAC T GAGGGACTTCCTGTAACCACTT
RPS13 GATGCTAAATTCCGCCTGAT TAGAGCAGAGGCTGTGGATG






Table 4. Western blot primary antibodies.
Antigen Supplier Catalog number Host species Dilution
Endoglin MJ7/18[24] Rat 1:2
ICAM-1 R&D Systems AF796 Goat 1:1 000
VCAM-1 Santa Cruz Biotechnology Sc-1504 Goat 1:1 000
Calnexin Stressgen SPA-860 Rabbit 1:10 000
https://doi.org/10.1371/journal.pone.0188204.t004
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Statistical analysis
The statistical analysis was performed using the GraphPad Prism 6.0 software (GraphPad Soft-
ware, Inc., CA, USA). All data are expressed as mean ± standard error of mean (SEM). The dif-
ferences between groups were examined for statistical significance using two-way ANOVA
with Bonferroni post-hoc analysis or the Student’s t-test. P values less than 0,05 were consid-
ered statistically significant.
Results
Soluble endoglin did not modify the membrane endoglin expression
To corroborate the animal model of human endoglin expression, we determined the concen-
tration of soluble human endoglin in mice plasma. The ELISA analysis showed elevated levels
of human endoglin in sEng+ mice and no soluble human endoglin in WT mice (Fig 2A).
Fig 2. Soluble human endoglin and membrane mouse endoglin in WT and sEng+ mice. (A) Soluble
human endoglin was measured by ELISA from plasma of WT and sEng+ mice. Data are expressed as mean
±SEM. n = 20 in each group of mice. *p<0,001, T test. (B) Mouse membrane endoglin amount of protein in
the lung was determined by western blot: +p<0,05 LPS vs control, two-way ANOVA. (C) Mouse membrane
endoglin amount of protein in the kidney was determined by western blot. Equal loading of samples was
confirmed by immunodetection of calnexin. Top: Representative immunoblots. Bottom: densitometric
analysis. Data are expressed as mean ±SEM. n = 5 in each group of mice.
https://doi.org/10.1371/journal.pone.0188204.g002
Soluble endoglin interferes with inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188204 November 16, 2017 8 / 24
We analyzed the amount of membrane endoglin protein in lung and kidney from control
and treated WT and sEng+ mice. We observed an increase in the amount of mouse membrane
endoglin protein after inflammation in lung and kidney tissues. However, no significant differ-
ences between sEng+ and WT mice were found (Fig 2B and 2C).
Soluble endoglin modified the histopathological changes induced by
inflammation in lung and kidney
ALI is a life-threatening, diffuse heterogeneous lung injury characterized by acute onset, pul-
monary edema and respiratory failure. The main features of experimental ALI include at least
three out of the following four features: histological evidence of tissue injury, such as the accu-
mulation of neutrophils in the alveolar or the interstitial space; alteration of the alveolar capil-
lary barrier, and as a consequence an increase in the total protein concentration of BAL; an
inflammatory response, such as an increase in the absolute number of neutrophils in the BAL;
and evidence of physiological dysfunction [25]. To evaluate the potential role of soluble endo-
glin in this process, histopathological analysis of LPS-induced ALI was performed. H&E stain-
ing of lung sections showed normal lung parenchyma and fewer macrophages in the alveolar
space of control WT and sEng+ mice, with no significant differences. In addition, indications
of marked inflammatory infiltrates, inter-alveolar septal thickening, and interstitial edema in
both WT and sEng+ mice lungs after LPS treatment were found (Fig 3A). Interestingly, the
patchy areas of neutrophilic infiltration into the lungs were lighter in sEng+ than in WT mice
(Fig 3A). Furthermore, severity of lung injury was also scored by a pathologist in a blind fash-
ion, using a semiquantitative histopathology score system already described [25], which classi-
fies lung injury into four categories: alveolar septae, alveolar hemorrhage, intra-alveolar fibrin,
and intra-alveolar infiltrates, as show the Table 1. Although soluble endoglin tended to reduce
the lung injury (Fig 3B) and intra-alveolar infiltrates score (Fig 3C), the observed differences
did not reach statistical significance.
Fig 4 shows H&E staining of kidney sections 48 h after ischemia-reperfusion. Normal renal
structure in the control WT and sEng+ mice was observed, without significant differences.
Also, indications of cortical and medullary hyperemia with areas of tubular necrosis in the
deep and superficial cortex, tubular cast and a significant expansion of the tubular structure
with destruction of the epithelium and inflammatory infiltrates were found in both WT and
sEng+ mice kidneys after ischemia-reperfusion (Fig 4A). Interestingly, the patchy areas of neu-
trophilic infiltration into the kidneys were lighter in sEng+ than in WT mice (Fig 4A). Further-
more, severity of kidney injury was also scored by a pathologist in a blind fashion using a
semiquantitative histopathology score system already describe [21], which classifies kidney
injury into three categories: glomerular damage, tubular obstruction and dilation and neutro-
philic infiltration, as show Table 2. Soluble endoglin induced a significant reduction in the
scores representing the level of injury (Fig 4B) and a significant reduction in neutrophil infil-
tration in ischemic kidneys from sEng+ mice was also observed as compared to the WT mice
(Fig 4C).
Soluble endoglin attenuated leukocyte recruitment
Inflammatory cell number in the BAL from WT and sEng+ mice increased significantly 48 h
after LPS nebulization compared to the control group, without significant differences between
WT and sEng+ control mice. Notably, it was found that soluble endoglin significantly reduced
leukocyte concentration in the BAL from LPS treated mice respect to the WT mice (Fig 5A).
The carrageenan model is an established model to study cellular recruitment in response to
inflammation which has been widely used in research for its ability to induce an acute
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inflammatory response. Thus, carrageenan-induced inflammation in the air-pouch model [26]
was investigated. In this study, the injection of sterile saline into the pouch produced no
inflammatory exudate and no cellular accumulation (leukocyte counts less than 7,0 x 105 i.e.
below the sensitivity of the hematology analyzer). In agreement with the above findings, air
pouch lavage from sEng+ mice, 24 h after carrageenan injection, contained a smaller number
of infiltrated leukocytes than WT mice (Fig 5B). Soluble endoglin significantly reduced total
accumulation of cells (63,9% inhibition), as well as lymphocytes (64,38% inhibition) (Fig 5B1),
neutrophils (46,3% inhibition) (Fig 5B2), basophils (66,04% inhibition) (Fig 5B3) and mono-
cytes (43,5% inhibition) (Fig 5B4).
Myeloperoxidase (MPO) is stored in azurophilic granules of polymorphonuclear neutro-
phils and macrophages, and is released into extracellular fluid in the setting of an inflamma-
tory process. The MPO activity in control and ischemic kidneys from WT and sEng+ mice
was determined. It was observed that MPO activity ischemic kidneys increased significantly 48
h after ischemia-reperfusion compared to the control group. Remarkably, soluble endoglin sig-
nificantly reduced the increase in MPO activity in ischemic kidneys (Fig 6). No significant dif-
ferences were found between WT and sEng+ mice under the control conditions.
Fig 3. Morphological lung changes after LPS treatment. (A) Representative images of hematoxylin and eosin
stained lung sections of five animals from each experimental group. Lungs were fixed with 4% paraformaldehyde,
embedded in paraffin, and cut into 5 μm thick sections before being stained. Photomicrographs were obtained with
a Nikon Eclipse E800 microscope. Both WT and sEng+ mice lungs show marked inflammatory infiltrates (arrow)
after LPS treatment, inter-alveolar septal thickening (arrow head), and interstitial edema (•). Magnification x200
and x400. (B) Severity of lung injury was scored by a pathologist using a semiquantitative histopathology score
system which evaluates lung injury in four categories: alveolar septae, alveolar hemorrhage, intra-alveolar fibrin,
and intra-alveolar infiltrates. Data are expressed as mean±SEM. n = 5 in each group of mice, +p<0,0001 vs
control, two-way ANOVA. (C) Evaluation score of intra-alveolar infiltrates. n = 5 in each group of mice.
https://doi.org/10.1371/journal.pone.0188204.g003
Soluble endoglin interferes with inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0188204 November 16, 2017 10 / 24
Soluble endoglin reduced proinflammatory cytokines levels
Inflammatory cytokines have been reported to be involved in neutrophil recruitment and
propagation of the inflammatory response. To further evaluate the reduction in inflammation
induced by soluble endoglin, levels of proinflammatory cytokines were measured in BAL and
air pouch lavage collected from WT and sEng+ mice. It was found that proinflammatory cyto-
kines (TNFα, IL1β and IL6) significantly increased in BAL and air pouch lavage in response to
LPS and carrageenan treatment respectively, compared to the control mice receiving saline
(Fig 7). Soluble endoglin significantly reduced IL1β and IL6 levels in LPS-treated mice (Fig
Fig 4. Morphological kidney changes after ischemia-reperfusion. (A) Representative images of hematoxylin and
eosin-stained kidney sections from five animals in each experimental group. Kidneys were fixed with 4% paraformaldehyde,
embedded in paraffin, and then cut into 5 μm thick sections before being stained. Photomicrographs were obtained with a
Nikon Eclipse E800 microscope. Both WT and sEng+ mice kidneys show cortical and medullary hyperemia with areas of
tubular necrosis found in the deep and superficial cortex, tubular cast and a significant expansion of the tubular structure
with destruction of the epithelium (arrow) and inflammatory infiltrates (•). Magnification x200 and x400. (B) Severity of kidney
injury was scored by a pathologist using a semiquantitative histopathology score system which evaluates kidney injury in
three categories: glomerular fibrosis, tubular obstruction and dilation and neutrophil infiltration. Data are expressed as mean
±SEM. n = 5 in each group of mice, +p<0,0001 vs control, two-way ANOVA. (C) Evaluation score of neutrophil infiltration.
n = 5 in each group of mice, *p<0,01 vs ischemic WT, T test.
https://doi.org/10.1371/journal.pone.0188204.g004
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7C–7F). However, soluble endoglin did not affect significantly TNFα and IL1β levels in air
pouch lavage, although it is observed a reduction tendency (Fig 7B and 7D). Moreover, no sig-
nificant differences were found between WT and sEng+ mice under control conditions.
The expression and presence of proinflammatory cytokines in lungs from WT and sEng+
mice were analyzed using Real-Time PCR and ELISA, respectively. It was found that IL1β
and IL6 expression was significantly increased in lungs after LPS treatment. Soluble endoglin
effectively decreased the levels of IL1β and IL6 expression compared with the WT LPS group
Fig 5. Leukocyte recruitment. (A) Leukocyte recruitment from control and LPS-treated WT and sEng+ mice.
Total leukocyte count was measured in BAL. Data are expressed as mean ±SEM. n = 6 in each group of
mice, #p<0,005 vs control sEng+, T test; *p<0,005 vs LPS WT, T test. (B) Leukocyte recruitment in the air
pouch lavage from carrageenan-treated WT and sEng+ mice. Data are expressed as mean ±SEM. n = 20 in
each group of mice. *p<0,001 vs carrageenan WT, T test. (B1) Subpopulations of recruited lymphocytes in air
pouch lavage (64,38% inhibition, *p<0,005 vs carrageenan WT, T test); (B2) Neutrophils (46,3% inhibition,
*p<0,01 vs carrageenan WT, T test); (B3) Basophils (66,04% inhibition, *p<0,005 vs carrageenan WT, T
test); (B4) Monocytes (43,5% inhibition, *p<0,05 vs carrageenan WT, T test). n = 20 in each group of mice.
Data are expressed as the percentage of sEng+ leukocytes with respect to the WT, mean ±SEM.
https://doi.org/10.1371/journal.pone.0188204.g005
Fig 6. Myeloperoxidase activity. MPO activity in kidneys from control and ischemia-treated WT and sEng
+ mice. MPO concentration was measured in kidney tissue and presented as MPO units per milligram of
tissue. n = 6 in each group of mice, *p<0,05 vs ischemic WT, #p<0,05 vs control sEng+, T test.
https://doi.org/10.1371/journal.pone.0188204.g006
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(Fig 8A and 8B), but was statistically significant. TNFα, IL1β, and IL6 protein levels were sig-
nificantly increased after the LPS inflammatory challenge in WT and sEng+ mice. It was
observed that soluble endoglin reduced the increment in TNFα and IL1β (Fig 8C and 8D), but
again the result was not statistically significant. No significant differences were found between
WT and sEng+ mice under control conditions.
Fig 7. Inflammatory cytokines in BAL and air-pouch lavage. Quantitative analysis of proinflammatory cytokines
(TNFα, IL1β and IL6) in BAL and air pouch lavage was performed by ELISA and presented as picograms per milliliter
of lavage. Data are expressed as mean ±SEM. n = 5 in each group of mice. (A) TNFα concentration in BAL,
+p<0,0001 LPS vs control, two-way ANOVA; (B) TNFα concentration in air pouch lavage, +p<0,05 carrageenan vs
control, two-way ANOVA; (C) IL1β concentration in BAL, *p<0,05 vs LPS WT, T test; (D) IL1β concentration in air
pouch lavage, +p<0,01 carrageenan vs control, two-way ANOVA; (E) IL6 concentration in BAL, #p<0,001 vs control
sEng+, T test; *p<0,05 vs LPS, T test; (F) IL6 concentration in air pouch lavage, *p<0,05 vs carrageenan WT, T test.
https://doi.org/10.1371/journal.pone.0188204.g007
Fig 8. Inflammatory cytokines in lung tissue. Quantitative analysis of inflammatory cytokines (TNFα, IL1β
and IL6) in lung tissue was performed by RT-PCR (A-B) and ELISA (C-E). Data are expressed as mean ±
SEM. n = 5 in each group of mice. (A) IL1β, +p<0,0005 LPS vs control, two-way ANOVA; (B) IL6, +p<0,0001
LPS vs control, two-way ANOVA; (C) TNFα, +p<0,005 LPS vs control, two-way ANOVA; (D) IL1β, +p<0,005
LPS vs control, two-way ANOVA; (E) IL6, +p<0,05 LPS vs control, two-way ANOVA.
https://doi.org/10.1371/journal.pone.0188204.g008
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The analysis of proinflammatory cytokine levels in plasma is shown in the Fig 9. I was
found that the concentration of TNFα, IL1β and IL6 were markedly increased in plasma after
LPS challenge. Soluble endoglin did not affect significantly the increase of TNFα, IL1β and IL6
levels in plasma compared with the WT LPS group, although it is observed a reduction ten-
dency in (Fig 9).
Soluble endoglin reduced inflammation-induced vascular permeability
The enhanced recruitment of polymorphonuclear cells in inflamed tissues is associated with
an increase in vascular permeability [27]. To evaluate the integrity of the capillary membrane
Fig 9. Inflammatory cytokines in plasma. Quantitative analysis of inflammatory cytokines (TNFα, IL1β and
IL6) in plasma was performed by ELISA. Data are expressed as mean ± SEM. n = 5 in each group of mice.
https://doi.org/10.1371/journal.pone.0188204.g009
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barrier and assess vascular leakage, the protein concentration in BAL and the air pouch lavage,
collected from WT and sEng+ mice, was determined. As shown in Fig 10A, the protein levels
in BAL were significantly increased in LPS-treated mice compared to the control mice. By con-
trast, soluble endoglin significantly reduced the increase in protein concentration in LPS-
treated mice. No significant differences between WT and sEng+ mice were found in control
conditions. Supporting these results, we also found that protein extravasation in the air pouch
lavage increased in carrageenan-treated animals (Fig 10B), while soluble endoglin significantly
reduced the increase in protein concentration in carrageenan-treated mice. No significant dif-
ferences between WT and sEng+ mice were found under the control conditions.
To further analyze vascular permeability, the fluorescence in BAL from LPS-treated WT
and sEng+ mice after FITC-Dextran intravenous injection was determined. Fig 10C shows the
significant reduction of fluorescence induced by soluble endoglin with respect to WT mice.
Also, pulmonary edema was examined by measuring the lung wet/dry weight ratio. Fig 10D
shows a significant decrease in the wet/dry weight ratio of sEng+ mice compared to the WT
LPS-aerosolized mice.
Fig 10. Vascular permeability. (A) Protein concentration in BAL. Data are expressed as mean ±SEM. n = 5 in each
group of mice. +p<0,0001 LPS vs control, two-way ANOVA; (B) Protein concentration in air pouch lavage. Data are
expressed as mean ±SEM. n = 5 in control mice and n = 20 in carrageenan-treated. #p<0,0001 vs control sEng+, T
test; *p<0,01 vs carrageenan WT, T test; (C) Fluorescence in BAL from LPS-treated WT and sEng+ mice. 24 h after
LPS exposure, 100 μl of 40kDa FITC-Dextran (25mg/ml) was injected into the retroorbital venous sinus, 30 min
before the mice were euthanized. BAL was collected. Data are expressed as mean ±SEM. n = 5 in each group of
mice. *p<0,05, T test; (D) Lung wet/dry weight ratios. Data are expressed as mean ±SEM. n = 5 in each group of
mice. *p<0,001, T test.
https://doi.org/10.1371/journal.pone.0188204.g010
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In addition, in vitro experiments showed that soluble endoglin decreased the permeability
to FITC-Dextran of a LPS-activated human endothelial cell EA.hy926 (Fig 11).
Endothelial permeability is regulated in part by the dynamic opening and closure of cell-
cell adherent junctions. In endothelial cells, adherent junctions are largely composed of vascu-
lar endothelial cadherin (VE-cadherin), an endothelium-specific member of the cadherin fam-
ily of adhesion proteins that binds, via its cytoplasmic domain, to several protein partners [28].
To evaluate the role of soluble endoglin in the capillary membrane barrier, VE-cadherin
amount of protein in lung tissue from WT and sEng+ mice was determined. The amount of
VE-cadherin was lower in LPS-treated mice compared to the control mice. Soluble endoglin
did not affect significantly the amount of VE-cadherin in LPS-treated mice, although it is
observed a reduction tendency (Fig 12A). Furthermore, it was found that VE-Cadherin
amount of protein was significantly lower in lungs after LPS challenge (Fig 12C). No signifi-
cant differences were found between WT and sEng+ mice under control conditions.
Soluble endoglin modified inflammation-induced endothelial adhesion
molecules expression
During inflammation, local innate cells release cytokines and vasoactive compounds that
induce activation of endothelial cells by increasing permeability and upregulating adhesion
molecules expression (i.e. Intercellular adhesion molecule (ICAM-1) and vascular cell adhe-
sion molecule (VCAM-1). The results of western blotting indicated that LPS treatment
resulted in a significant induction of ICAM-1, VCAM-1 in lung tissues. Soluble endoglin
decreased this adhesion molecules amount of protein in LPS-treated mice (Fig 12B). VCAM
and E-selectin mRNA expression were significantly increased in kidneys after ischemia-reper-
fusion. Soluble endoglin significantly decreased the levels of VCAM and E-selectin mRNA
Fig 11. Effect of circulating soluble endoglin on cell permeability. The permeability was determined in
endothelial EA.hy926 cells cultured in transwell plates until they reached confluence. Upper chamber media,
containing LPS (1 μg/ml) and soluble endoglin (500 ng/ml) for their respective treatments, were replaced with
FITC-Dextran (40 kDa) at 1 mg/ml in DMEM. After 24 h at 37˚C, the inserts were removed, and the amount of
fluorescence in the bottom chambers was measured using a fluorescence plate reader. Data are presented
as percentage of fluorescence versus Control. Data are expressed as mean ±SEM. n = 6 in each group of
mice. T test, p = 0,09.
https://doi.org/10.1371/journal.pone.0188204.g011
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expression compared to the WT ischemia group (Fig 12D and 12E). No significant differences
between WT and sEng+ mice under the control conditions were found.
Discussion
There is a growing body of research supporting the role of inflammation in cardiovascular dis-
eases. Hypertension is the most common chronic disease and the major cause of heart failure,
stroke, chronic kidney disease and mortality. Experimental and clinical evidence suggests
inflammation has a critical role in the development of hypertension [29,30]. Inflammation is
one of the main reasons why people with diabetes experience heart attacks, strokes, kidney
pathologies and other related complications [31–34]. Most diabetic treatments also exert anti-
inflammatory effects [32]. Atherosclerosis also has been recognized as an inflammatory disease
of the arterial wall [35]. Furthermore, preeclampsia, a serious condition that affects 5–10% of
all pregnancies [36], characterized by hypertension and proteinuria [37] and other systemic
disturbances, [38] is also associated with a systemic inflammatory response [39–42]. In addi-
tion, circulating levels of IL6, tumor necrosis factor alpha (TNFα) and monocyte chemoattrac-
tant protein 1 (MCP-1) have been found to be elevated in preeclampsia [43].
Interestingly, the above mentioned diseases exhibit elevated levels of circulating soluble
endoglin, including hypercholesterolemia [44], hypertension [16], atherosclerosis [45], type II
diabetes mellitus [8] and preeclampsia [46]. Soluble endoglin has been shown to be a potential
biomarker of these diseases [47], however, the direct relationship between the elevated levels of
soluble endoglin and the inflammatory processes involved in these diseases still remains to be
elucidated.
The sEng+ mice used in the present study have elevated plasma levels of soluble human
endoglin and develop mild hypertension and proteinuria as it has been published [16].
Fig 12. Effect of circulating soluble endoglin on endothelial adhesion molecules. (A) VE-Cadherin
amount of protein and mRNA expression were determined by western blot: +p<0,0001 LPS vs control, two-
way ANOVA; and RT-PCR (C): +p<0,0001 LPS vs control, #p<0,05 vs control sEng+; two-way ANOVA. (B)
VCAM and ICAM amount of protein was determined by western blot, +p<0,05 LPS vs control, two-way
ANOVA. (D)VCAM mRNA expression was also determined by RT-PCR in kidney tissue: *p<0,01 vs ischemic
WT, #p<0,005 vs control sEng+, T test. Equal loading of samples was confirmed by immunodetection of
calnexin. Top: Representative immunoblots. Bottom: densitometric analysis. Data are expressed as mean ±
SEM. n = 5 in each group of mice. (E) E-Selectin mRNA expression was determined by RT-PCR. E-Selectin,
*p<0,05 vs ischemia WT, T test.
https://doi.org/10.1371/journal.pone.0188204.g012
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Inflammation induce an increase in the amount of mouse membrane endoglin protein after
inflammation in lung and kidney tissues without significant differences between sEng+ and
WT mice. Recently, it has been shown, in an in vitro study, that soluble endoglin induce an
increase in the levels of membrane endoglin [48]. However, the effects of soluble endoglin on
endothelial cells in culture are not demonstrated to be mediated by membrane endoglin.
Accordingly, our work supports the hypothesis that soluble endoglin has a role itself rather
than exerts its function by antagonizing the role of membrane endoglin. Some studies have
postulated that the effect of soluble endoglin is produced by antagonizing the effect of mem-
brane endoglin or by sequestering the ligand. Soluble endoglin can bind several ligands,
among them TGF-β1, BMP-9 and BMP-10 [5,14]. When soluble endoglin binds circulating
TGF-β1, the availability of this cytokine to interact with its membrane receptors decreases, as
soluble endoglin is unable to interact directly with the extracellular region of TGF-β receptors
type I and type II [15]. Further studies are needed to elucidate the relationship between the
effects of soluble endoglin and membrane endoglin.
In this study, we show that high levels of soluble endoglin alone do not modify the inflam-
matory state of sEng+ mice. Our results show no differences in the inflammatory state (leuko-
cyte infiltration, inflammatory cytokines, vascular permeability or adhesion molecules
expression) between WT and sEng+ mice under control conditions. In agreement to this find-
ing, Nemeckova et al., also show that high levels of soluble endoglin alone do not induce differ-
ences in leukocyte recruitment, inflammatory cytokines, vascular permeability or adhesion
molecules expression in the tissues of both sEng+ and control mice [44].
In addition, it has been shown that soluble endoglin does not induce endothelial dysfunc-
tion under control conditions in vivo [44,49]. Recently, Varejckova et al. found, in an in vitro
study, that soluble endoglin treatment results in an activation of NF-κB/IL6 expression, with-
out significant effects on other markers of endothelial dysfunction and inflammation, includ-
ing eNOS, peNOSS1177, VCAM-1, COX-1, COX-2 and ICAM-1 [48]. The fact that other NF-
κB-regulated pro-inflammatory proteins were not affected by the addition of soluble endoglin
suggests that soluble endoglin treatment by itself does not induce an inflammatory response in
endothelial cells in this experimental design.
Our results do not rule out the possibility that soluble endoglin may contribute to the alter-
ation of the inflammatory state when accompanied by a second hit, similar to what occurs in
inflammatory diseases. To this purpose, an animal model was employed where increasing cir-
culating levels of soluble endoglin is matched with an inflammatory process. The animals
experienced acute inflammation using three approaches: LPS nebulization, carrageenan air
pouch and renal ischemia-reperfusion. Systemic inflammation is rapidly activated by LPS
administration in experimental models, which subsequently increases the plasma levels of
inflammatory cytokines (TNFα or IL1β) and oxygen-free radicals [50,51].
In the present study, LPS nebulization induces tissue damage, characterized by increased
lung water content, disruption of lung architecture, extravasation of red blood cells and accu-
mulation of inflammatory cells. These results are consistent with the observations of other
authors in LPS-treated animals [52–54]. Ischemia-reperfusion injury (IRI) is characterized by
restriction of blood supply to an organ followed by restoration of blood flow and re-oxygen-
ation. This phenomenon exacerbates tissue damage by initiating an inflammatory cascade
including reactive oxygen species, cytokines, chemokines, and leukocytes activation [55–57].
The lung and kidney injury induced by the inflammatory agents was reduced in sEng
+ mice, especially the intra-alveolar and kidney infiltrates, suggesting a possible decrease of
inflammation induced by soluble endoglin. To deepen into this effect, the leukocyte number
in BAL and air pouch lavage was evaluated. Our results demonstrate that soluble endoglin
reduced the recruitment and transmigration of leukocyte in this mice model. In addition, we
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observed a significant reduction of neutrophil infiltration in LPS-treated lungs and ischemic
kidneys from sEng+ with respect to WT mice. Supporting this observation, Rossi et al., showed
that soluble endoglin inhibits leukocyte adhesion and transmigration in vitro [58]. They also
demonstrated that leukocyte transmigration was lower in endoglin deficient mice and that the
RGD endothelial endoglin motif interacts with the leukocyte integrin α5β1, suggesting a regu-
latory role for membrane endoglin in transendothelial leukocyte trafficking. The interaction
between soluble endoglin and leukocyte integrins could explains our results regarding leuko-
cyte transmigration, however an integrin-independent effect of soluble endoglin should not be
discarded. Since soluble endoglin could bound the leukocytes integrins and prevent the trans-
migration through the endothelial cells, although the permeability and/or the proinflammatory
cytokines have to be considered. In addition, soluble endoglin contains the binding site for dif-
ferent members of the TGF-β superfamily and may act as a scavenger of circulating ligands,
preventing their binding to the functional receptors [5,9]. However, the possible role of soluble
endoglin antagonizing the effect of membrane endoglin is a hypothesis that is not proven yet.
Our results demonstrate the involvement of soluble endoglin in the regulation of permeability
and proinflammatory cytokines. These are important and novelty mechanisms of the inflam-
matory process regulation that here demonstrate to be regulated by soluble endoglin. Addi-
tionally, the mechanisms through which soluble endoglin prevents inflammation were
studied. It is well known that LPS and carrageenan stimulate macrophages/monocytes to
sequentially release proinflammatory cytokines and that TNFα and IL6 participate in the early
development of inflammation [59,60]. In the current study, we found that LPS significantly
increases BAL and tissue proinflammatory cytokines TNFα, IL1β and IL6, whereas soluble
endoglin prevents this increase.
Jezkova et al. found that in female, but not in male mice, proinflammatory markers were
higher in the aortas of sEng+ mice 3 months after the intake of high-fat diet [61]. Our study
differs substantially from that of Jezkova et al. because, we induce an acute inflammation
under the effect of circulating soluble endoglin. While in the Jezkova study inflammatory
markers are studied 3 months after the insult, there may be other processes involved in the
analyzed response. It also should be considered that differences in inflammatory markers
attributed to soluble endoglin appear only in female mice, which means that the mechanisms
involved in the process could be related with sex factors.
Modifications in the inflammatory process may explain damage to the vascular endothe-
lium which leads to the capillary leak [62–64]. In this study, we clearly demonstrate that
inflammation-induced vascular permeability is reduced by soluble endoglin. To our knowl-
edge, this is the first time that the relationship between circulating soluble endoglin and
inflammation-induced vascular permeability has been shown. The formation of new immature
and leaky vessels along with inflammatory remodeling accompany the development of numer-
ous diseases beyond cancer, and present an opportunity for passive accumulation of intrave-
nously administered nanomedicines in many pathological tissues [65]. Soluble endoglin could
represent an opportunity and create new therapy and prevention technologies for many disor-
ders. For example, therapeutic strategies to limit inflammatory cells and their products have
been successful in pre-clinical tumor models [66]. Furthermore, in the systemic pregnancy
syndrome of preeclampsia, both, systemic inflammation and soluble endoglin, have been
found elevated [67]. However, the fact that both parameters are elevated in preeclampsia does
not demonstrate that soluble endoglin induce inflammation. We do not know how the inflam-
mation in preeclampsia would be in the absence of soluble endoglin, it might be that we would
found a greater inflammation than that observed with elevated levels of circulating endoglin.
Preeclampsia is a complex process that evolves throughout pregnancy. Effectively soluble
endoglin has been shown to be a molecule involved in the pathogenesis of preeclampsia [16].
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Our results do not contradict this affirmation. Numerous studies have shown that soluble
endoglin is elevated as early as 11–13 weeks of gestation before the development of preeclamp-
sia [67]. In contrast, neutrophil activation and elevation of Th1 pro-inflammatory cytokines
have been shown to occur at the time of diagnosis of preeclampsia [67]. The models of acute
inflammation in the presence of circulating endoglin used in this study could allow us to
approach a hypothetical onset of preeclampsia, where the presence of high levels of soluble
endoglin precedes the inflammatory processes. In this context, the reduction of inflammation
induced by circulating soluble endoglin may explain the antiangiogenic effect of soluble endo-
glin in the early stages of preeclampsia. Hence, the initiation of angiogenesis is often associated
with an increased capillary permeability that serves to enrich the adjacent interstitial compart-
ment with plasma components. Inflammation and angiogenesis are thereby linked processes,
but exactly how they are related has not been well understood [68].
This study also shows that soluble endoglin prevents the increased expression of adhesion
molecules, ICAM, VCAM and E-selectin induced by the inflammatory stimulus. ICAM,
VCAM and E-selectin are essential for stable adhesion and transmigration of leukocytes in
most types of inflammatory processes and blocking antibodies against ICAM-1 inhibits leuko-
cyte adhesion. The reduction in the adhesion molecules expression can lead to a decrease in
the number of transmigrated leukocytes and thus could explain the decrease of inflammatory
cytokines in the presence of soluble endoglin. The inflammation-induced disruption of adher-
ent junctions is associated to the decreased expression of VE-cadherin mRNA. One conse-
quence of adherent junction disassembly is that the compromised endothelial cell barrier lead
to an influx of solutes and increased neutrophil infiltration. Therefore, circulating soluble
endoglin could prevent the increase in inflammation-induced vascular permeability that
occurs during inflammation-related diseases, preventing the increase of inflammatory cyto-
kines due to the reduction of inflammatory cells recruitment.
This work brings out an interesting relationship between circulating soluble endoglin and
diseases with an inflammatory component. When elevated levels of soluble endoglin are
accompanied by an inflammatory process, the result is a decrease in vascular permeability, a
reduction in the proinflammatory biomarkers TNFα, IL1β and IL6, and less leukocyte recruit-
ment and leukocyte tissue infiltration. Taken together, these results, indicate that circulating
soluble endoglin may contribute to a lesser increase in the inflammatory response.
These encouraging results represent a turning point in the understanding of the role of sol-
uble endoglin in the pathophysiology of various cardiovascular diseases, and, imply that solu-
ble endoglin has an impact on the inflammatory state during inflammatory-related diseases.
These results provide a better understanding of the inflammatory basis of these diseases, and
open new perspectives leading to the development of novel and targeted approaches for the
prevention and treatment of cardiovascular disease.
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